Weekly Digest – June 2026 Weekly Digest – June 2026 22 June 2026: SystImmune secures first China approval for Iza-bren in Nasopharyngeal carcinoma Biokin Pharma has received NMPA approval for Iza-bren for the treatment of recurrent or metastatic nasopharyngeal carcinoma […]
Weekly Digest – June 2026 Weekly Digest – June 2026 24 June 2026: U.S. FDA approves Trodelvy for first-line treatment of metastatic TNBC Gilead Sciences has received U.S. FDA approval for Trodelvy as a first-line treatment for adults with unresectable […]
Weekly Digest – June 2026 Weekly Digest – June 2026 23 June 2026: European Commission approves Trodelvy for first-line metastatic TNBC Gilead Sciences has received European Commission approval for Trodelvy as a first-line treatment for adult patients with unresectable locally […]
Weekly Digest – June 2026 Weekly Digest – June 2026 24 June 2026: European Commission approves PADCEV as perioperative treatment for cisplatin-ineligible patients with resectable MIBC Astellas and Pfizer have received European Commission approval for PADCEV in combination with KEYTRUDA […]
Weekly Digest – June 2026 Weekly Digest – June 2026 23 June 2026: NMPA accepts Tecotabart Vedotin NDA for third-line CLDN18.2+ Gastric cancer The NDA for LM-302, a CLDN18.2-targeting antibody-drug conjugate developed by Sino Biopharmaceutical, has been accepted by China’s […]
Weekly Digest – June 2026 Weekly Digest – June 2026 22 June 2026: Lonza and InduPro announce licensing agreement to advance next-generation ADC therapeutics Lonza and InduPro have entered into a licensing agreement to advance next-generation antibody-drug conjugate therapeutics, providing […]
Weekly Digest – June 2026 Weekly Digest – June 2026 16 June 2026: Zai Lab’s Zocilurtatug pelitecan receives EMA Orphan Drug Designation for pulmonary Neuroendocrine carcinoma Zai Lab has received Orphan Drug Designation from the European Medicines Agency for Zocilurtatug […]
Weekly Digest – June 2026 Weekly Digest – June 2026 17 June 2026: FDA Accepts sBLA for Genentech’s Lunsumio and Polivy combination in relapsed/refractory Large B-cell lymphoma Genentech has announced that the U.S. FDA has accepted a supplemental Biologics License […]
Weekly Digest – June 2026 Weekly Digest – June 2026 12 June 2026: Oncopeptides submits EMA application for Pepaxti label expansion to third-line treatment Oncopeptides has submitted a type 2 variation application to the European Medicines Agency seeking to expand […]
Weekly Digest – June 2026 Weekly Digest – June 2026 17 June 2026: Henlius’ HLX43 in combination with Serplulimab phase 2 NSCLC trial approved in Australia Henlius has received approval from Australia’s Human Research Ethics Committee, with acknowledgment from the […]
